ロード中...
NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy
SIMPLE SUMMARY: eIF4A-targeted translational inhibitors, such as silvestrol and its analogues, have emerged as strong anticancer therapies. Here, we tested the efficacy of eIF4A inhibition across a large and diverse panel of cancer cell lines and found B cell lymphomas to be the most sensitive group...
保存先:
| 出版年: | Cancers (Basel) |
|---|---|
| 主要な著者: | , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MDPI
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7915661/ https://ncbi.nlm.nih.gov/pubmed/33562682 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13040639 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|